TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $62,546 | +783.7% | 7,609 | +728.9% | 0.00% | – |
Q1 2024 | $7,078 | +28.0% | 918 | +49.3% | 0.00% | – |
Q4 2023 | $5,529 | +735.2% | 615 | +731.1% | 0.00% | – |
Q3 2023 | $662 | -41.8% | 74 | 0.0% | 0.00% | – |
Q2 2023 | $1,137 | -86.3% | 74 | -79.9% | 0.00% | – |
Q1 2023 | $8,276 | +431.9% | 368 | +397.3% | 0.00% | – |
Q4 2022 | $1,556 | -48.1% | 74 | -30.8% | 0.00% | – |
Q3 2022 | $3,000 | +50.0% | 107 | +5.9% | 0.00% | – |
Q2 2022 | $2,000 | -94.7% | 101 | -93.2% | 0.00% | – |
Q1 2022 | $38,000 | +1166.7% | 1,487 | +1372.3% | 0.00% | – |
Q4 2021 | $3,000 | +50.0% | 101 | 0.0% | 0.00% | – |
Q3 2021 | $2,000 | 0.0% | 101 | -20.5% | 0.00% | – |
Q2 2021 | $2,000 | -33.3% | 127 | +25.7% | 0.00% | – |
Q1 2021 | $3,000 | 0.0% | 101 | 0.0% | 0.00% | – |
Q4 2020 | $3,000 | – | 101 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |